Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 33, Issue 8, 2009, Pages 409-417

  Fang, Wenfang B ^a   Chang, Yan ^a   McCance Katz, Elinore F ^b   Moody, David E ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COMPLEMENTARY DNA; CYTOCHROME P450; MORPHINE DERIVATIVE; NALOXONE; NALTREXONE; NORNALOXONE; OXYMORPHONE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIVER MICROSOME; PROTEIN EXPRESSION; ROOM TEMPERATURE; SOLID PHASE EXTRACTION; URINALYSIS; URINARY EXCRETION;

EID: 70349873940     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.8.409     Document Type: Article

References (30)

1. W.R. Martin, C.G. Eades, J.A. Thompson, R.E. Huppler, and P. E. Gilbert. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197: 517-532 (1976).
2. P.E. Gilbert andW.R. Martin. The effects of morphine- and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 198: 66-82 (1976).
3. M.J. Brownstein. A brief history of opiates, opioid peptides, and opioid receptors. Proc. Natl. Acad. Sci. USA 90: 5391-5393 (1993).
4. T. Reisine. Neurotransmitter receptors V opiate receptors. Neuropharmacology 34: 463-472 (1995).
5. W.R. Martin. Naloxone. Ann. Intern. Med. 85: 765-768 (1976).
6. W. Ling and D.R.Wesson. Drugs of abuse - opiates.West. J.Med. 152: 565-572 (1990).
7. S. Helm, II, A.M. Trescot, J. Colson, N. Sehgal, and S. Silverman. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician 11: 225-235 (2008).
8. F.J. Vocci, J. Acri, and A. Elkashef. Medication development for addictive disorders: the state of the science. Am. J. Psychiatry 162: 1432-1444 (2005).
9. S.H.Weinstein, M. Pfeffer, and J.M. Schor. Metabolism and pharmacokinetics of naloxone. Adv. Biochem. Psychopharmacol. 8: 525-535 (1974).
10. D.S. Harris, R.T. Jones, S. Welm, R.A. Upton, E. Lin, and J. Mendelson. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 61: 85-94 (2000).
11. C.N. Chiang and R.L. Hawks. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 70: S39-S47 (2003).
12. B.A. Berkowitz, S.H. Ngai, J. Hempstead, and S. Spector. Disposition of naloxone: use of a new radioimmunoassay. J. Pharmacol. Exp. Ther. 195: 499-504 (1975).
13. P.J. Meffin and K.J. Smith. Gas chromatographic analysis of naloxone in biological fluids. J. Chromatogr. B 183: 352-356 (1980).
14. L.A. Asali, R.L. Nation, and K.F. Brown. Determination of naloxone in blood by high-performance liquid chromatography. J. Chromatogr. B 278: 329-335 (1983).
15. M.D. Terry, G.H. Hisayasu, J.W. Kern, and J.L. Cohen. High-performance liquid chromatographic analysis of naloxone in human serum. J. Chromatogr. B 311: 213-217 (1984).
16. H. Albeck, S. Woodfield, and M.J. Kreek. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J. Chromatogr. B 488: 435-445 (1989).
17. R.W. Reid, A. Deakin, and D.J. Leehey. Measurement of naloxone in plasma using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 614: 117-122 (1993).
18. M. Franklin and J. Odontiadis. Determination of naloxone in human plasma by high-performance liquid chromatography with coulometric detection. J. Chromatogr. B 679: 199-203 (1996).
19. D.E. Moody, M.H. Slawson, E.C. Strain, J.D. Laycock, A.C. Spanbauer, and R.L. Foltz. A liquid chromatography-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 306: 31-39 (2002).
20. U.S. FDA. Guidance for industry: bioanalytical method validation (2001). http://www.fda.gov/cder/guidance/4252fnl.pdf. (accessed June 2004).
21. F.T. Peters. Method validation using LC-MS. In Applications of LC-MS in Toxicology, A. Polettini, Ed. Pharmaceutical Press, London, U.K., 2006, pp 71-95.
22. E.F.McCance-Katz,D.E.Moody,G.D.Morse,Q.Ma, R.DiFrancesco, G. Friedland, P. Pade, and P.M. Rainey. Interaction between buprenorphine and atazanavir and atazanavir/ritonavir. Drug Alcohol Depend. 91: 269-278 (2007).
23. D.E. Moody, Y. Chang,W. Huang, and E.F. McCance-Katz. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin. Pharmacol. Toxicol. 105: 211-215 (2009).
24. J.A. Neff and D.E. Moody. Differential N-demethylation of l-α- acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem. Biophys. Res. Commun. 284: 751-756 (2001).
25. Y. Chang, D.E. Moody, and E.F. McCance-Katz. Novel metabolites of burprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos. 34: 440-448 (2006).
26. A.C. Nelson, W. Huang, and D.E. Moody. Variables in human liver microsome preparation: impact on the kinetics of L-α-acetylmethanol (LAAM) N-demethylation and dextromethorphan Odemethylation. Drug Metab. Dispos. 29: 319-325 (2001).
27. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275 (1951).
28. T.M. Annesley. Ion suppression in mass spectrometry. Clin. Chem. 49: 1041-1044 (2003).
29. E.C. Strain, D.E.Moody, K.B. Stoller, S.L.Walsh, and G.E. Bigelow. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend. 74: 37-43 (2004).
30. 3H in normal and narcotic dependent man. J. Pharmacol. Exp. Ther. 187: 575-580 (1973).